Time to market drives billions in value but fragmented systems create hidden risks.
The pharmaceutical industry has never been slow, but the arrival of blockbuster GLP-1 drugs has accelerated its pace to a new extreme.
For companies developing these diabetes and obesity treatments, even a single week’s delay in reaching the market can translate into millions in missed revenue.
Under this pressure, manufacturers are being forced to rethink how they operate. Speed is no longer just one performance metric among many – it has become central to the entire business model, reshaping how the industry approaches production from the ground up.
Check out the rest of the feature here
